These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 19685457)

  • 1. Editorial: Biotech in the financial crisis.
    Jungbauer A
    Biotechnol J; 2009 Aug; 4(8):1095. PubMed ID: 19685457
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
    Gruber AC
    Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Private biotech 2004--the numbers.
    Hodgson J
    Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 5. White biotech and the financial crisis.
    Rabinovich M
    Biotechnol J; 2009 Aug; 4(8):1117-23. PubMed ID: 19685465
    [No Abstract]   [Full Text] [Related]  

  • 6. BTJ Forum: Biotech in the financial crisis.
    Biotechnol J; 2009 Aug; 4(8):1108-10. PubMed ID: 19685461
    [No Abstract]   [Full Text] [Related]  

  • 7. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech sector ponders potential 'bloodbath'.
    Mitchell P
    Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
    [No Abstract]   [Full Text] [Related]  

  • 9. The development of China's medical biotech industry needs to be driven by innovation.
    Yu Z; Dai Y
    Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 11. The promise of South African biotech.
    Akermann B; Kermani F
    Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 13. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 14. The number on biotech indexes.
    Jacobs T
    Nat Biotechnol; 2005 Nov; 23(11):1356. PubMed ID: 16273059
    [No Abstract]   [Full Text] [Related]  

  • 15. Public biotechnology 2003-the numbers.
    Lähteenmäki R; Baker M
    Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
    [No Abstract]   [Full Text] [Related]  

  • 16. Today's biotech industry in India.
    Suresh N
    Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434
    [No Abstract]   [Full Text] [Related]  

  • 17. Perspective: A tale of 'cautious pessimism': Biotechnology, recession and the 'new economy'.
    Kewell B; Webster A
    Biotechnol J; 2009 Aug; 4(8):1106-8. PubMed ID: 19685467
    [No Abstract]   [Full Text] [Related]  

  • 18. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive compensation at private biotech companies: a competitive environment.
    Rychlik B; Dipierro M
    Nat Biotechnol; 2008 Jan; 26(1):133-4. PubMed ID: 18183026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.